{"id":390834,"date":"2017-11-28T00:00:00","date_gmt":"2017-11-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0026-2017-biopharma-unipolar-depression-access-and-reimbursement-major-depressive-disorder-us-2017\/"},"modified":"2026-04-25T11:39:03","modified_gmt":"2026-04-25T11:39:03","slug":"acrecg0026-2017-biopharma-unipolar-depression-access-and-reimbursement-major-depressive-disorder-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acrecg0026-2017-biopharma-unipolar-depression-access-and-reimbursement-major-depressive-disorder-us-2017\/","title":{"rendered":"Unipolar Depression | Access and Reimbursement | Major Depressive Disorder | US | 2017"},"content":{"rendered":"<p>Numerous drugs across multiple drug classes are available for the treatment of\u00a0<abbr data-original-title=\"major depressive disorder\" title=\"\">MDD<\/abbr>. Yet current therapies are not sufficiently effective in all patients, and\u00a0those patients\u00a0with\u00a0<abbr data-original-title=\"treatment-resistant depression\" title=\"\">TRD<\/abbr>\u00a0have become the target of drug development. Furthermore, the treatment armamentarium is growing increasingly genericized, which has improved patient access to antidepressants as well as eased restrictions on off-label adjunctive use of atypical antipsychotics. At the same time, the expanding generics presence has given payers greater leverage to control drug-treatment costs in\u00a0<abbr data-original-title=\"major depressive disorder\" title=\"\">MDD<\/abbr>. Understanding the current and expected influence of clinical metrics and value for dollar on market access and medical practice are key for developers of new therapies for\u00a0<abbr data-original-title=\"major depressive disorder\" title=\"\">MDD<\/abbr>.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What factors influence physician prescribing of select therapies for\u00a0<abbr data-original-title=\"major depressive disorder\" title=\"\">MDD<\/abbr>? Which therapies are succeeding and which are stumbling based on these factors?<\/li>\n<li>In this mature and highly genericized treatment landscape, what actions can marketers of therapies used to treat\u00a0<abbr data-original-title=\"major depressive disorder\" title=\"\">MDD<\/abbr>\u00a0employ to attain successful market access and thus overall sales?<\/li>\n<li>How are\u00a0<abbr data-original-title=\"managed care organization\" title=\"\">MCO<\/abbr>s performing value assessments for\u00a0<abbr data-original-title=\"major depressive disorder\" title=\"\">MDD<\/abbr>\u00a0therapies, and what are the preferred pharmacoeconomic models?<\/li>\n<li>To which of their\u00a0<abbr data-original-title=\"major depressive disorder\" title=\"\">MDD<\/abbr>\u00a0patients do physicians anticipate prescribing the emerging therapies ALKS-5461 (Alkermes), esketamine (Janssen), and rapastinel (Allergan)? How do payers expect to reimburse these therapies?<\/li>\n<\/ul>\n<p><strong>Product Description:<\/strong><\/p>\n<p>Access &#038; Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.<\/p>\n","protected":false},"template":"","class_list":["post-390834","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-therapy-areas-unipolar-depression","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390834\/revisions"}],"predecessor-version":[{"id":576786,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390834\/revisions\/576786"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}